These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36185192)

  • 1. Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy.
    Zhu L; Zhao Z; Liu A; Wang X; Geng X; Nie Y; Zhao F; Li M
    Front Oncol; 2022; 12():774816. PubMed ID: 36185192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy.
    Gao LR; Li C; Han W; Ni W; Deng W; Tan L; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang W; Liu W; Deng L; Wang X; Zhang T; Wang J; Zhai Y; Bi N; Wang L; Hui Z; Li YX; Xiao Z
    Ther Adv Med Oncol; 2022; 14():17588359221108693. PubMed ID: 35923925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Wang YM; Lo CM; Chou SY; Huang CH; Shih LH; Chen SW; Li SH
    Oncotarget; 2017 Nov; 8(56):96190-96202. PubMed ID: 29221198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study.
    Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Liu T; Zheng Q; Zheng H; Yang J; Wang Z; Li H; Liu L; Yao Q; Li J; Cheng W; Chen X
    Front Nutr; 2022; 9():896847. PubMed ID: 35990358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study.
    Jo YY; Yu J; Song KJ; Jang JY; Yoo YJ; Kim SB; Park SR; Kim YH; Kim HR; Kim JH
    Radiother Oncol; 2021 Sep; 162():112-118. PubMed ID: 34265356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Harada H; Yamashita K; Katada C; Ishiyama H; Soeno T; Washio M; Sakuraya M; Ushiku H; Niihara M; Hosoda K; Hiki N
    Langenbecks Arch Surg; 2020 Sep; 405(6):767-776. PubMed ID: 32671456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery.
    Kong M; Shen J; Zhou C; Yang H; Chen B; Zhu C; Wang G
    Ann Transl Med; 2020 Sep; 8(18):1129. PubMed ID: 33240978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abdominal lymph node metastasis in non-surgical esophageal squamous cell carcinoma: prognostic significance and a novel staging strategy.
    Zhao Z; Wang H; Liu Y; Li M; Li M
    Front Oncol; 2023; 13():1234426. PubMed ID: 37876971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph Node Metastases Diagnosed by
    Ogino I; Watanabe S; Misumi T; Hata M; Kunisaki C
    Anticancer Res; 2019 Sep; 39(9):4977-4985. PubMed ID: 31519604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Shih LH; Chen SW; Li SH
    Sci Rep; 2018 Oct; 8(1):15073. PubMed ID: 30305678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis for local radical treatment in patients with esophageal squamous cell carcinoma with low-risk oligometastatic recurrence after curative resection: a retrospective cohort study.
    Li T; Ke D; Fu X; Dai Y; Lin J; Anker CJ; Bai Z; Li J
    J Gastrointest Oncol; 2024 Jun; 15(3):807-817. PubMed ID: 38989428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
    Yagi K; Toriumi T; Aikou S; Yamashita H; Seto Y
    Ann Gastroenterol Surg; 2021 Jul; 5(4):436-445. PubMed ID: 34337292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus cisplatin and fluorouracil as induction chemotherapy followed by definitive chemoradiotherapy for patients with cT4 and/or supraclavicular lymph node metastasis (M1Lym) of esophageal squamous cell carcinoma.
    Hokamura N; Fukagawa T; Fukushima R; Kiyokawa T; Horikawa M; Kumata Y; Suzuki Y; Midorikawa H
    Surg Today; 2024 Nov; 54(11):1410-1413. PubMed ID: 38769180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.